LBA2 The DANTE phase III trial comparing 1 year versus 2 years of anti-PD1 immunotherapy as first-line treatment for metastatic melanoma: Health economics analysis

Gkountouras, G. orcid.org/0000-0003-2093-5359, Meads, D., Mujica-Mota, R. et al. (16 more authors) (2025) LBA2 The DANTE phase III trial comparing 1 year versus 2 years of anti-PD1 immunotherapy as first-line treatment for metastatic melanoma: Health economics analysis. In: Immuno-Oncology Technology. ESMO Immuno-Oncology Congress 2025, 10-12 Dec 2025, London, United Kingdom. Vol 28. Elsevier. Article no: 101552, p. 101552. ISSN: 2590-0188.

Metadata

Item Type: Conference abstract
Authors/Creators:
Copyright, Publisher and Additional Information:

This is an open access conference abstract under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Dates:
  • Published (online): 26 December 2025
  • Published: 26 December 2025
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds)
Date Deposited: 15 Jan 2026 13:05
Last Modified: 13 Mar 2026 12:17
Published Version: https://www.sciencedirect.com/science/article/pii/...
Status: Published
Publisher: Elsevier
Identification Number: 10.1016/j.iotech.2025.101552
Open Archives Initiative ID (OAI ID):

Export

Statistics

View Altmetric information about this item.


CORE (COnnecting REpositories)